Ovarian cancer cells induce premature aging in adipose-derived stem cells (ADSCs) through extracellular vesicles carrying IL-1β, activating the NF-κB inflammatory pathway and creating senescent cells that fuel tumor growth. Treatment with the senolytic combination dasatinib plus quercetin, or resveratrol alone as an NF-κB inhibitor, eliminated these senescent ADSCs and significantly reduced cancer progression and metastasis in experimental models. This represents a paradigm shift in cancer treatment strategy. Rather than targeting tumor cells directly, eliminating the aged cellular environment that cancers exploit offers a novel therapeutic approach. The findings are particularly relevant given that ovarian cancer preferentially spreads to fat-rich tissues like the omentum. However, this remains preclinical research requiring human validation. The senolytic field has shown mixed clinical results, and the complex interplay between aging, inflammation, and cancer biology in humans may differ substantially from laboratory models. Still, the mechanistic clarity around IL-1β delivery and NF-κB activation provides concrete therapeutic targets that could translate to clinical applications for patients with advanced ovarian cancer.